Exchange: NASDAQ·Updated 07:59 PM EST
PYXS logo

PYXS Pyxis Oncology Inc

$1.81
$0.13
(7.74%)
Today
Closed $1.81
$0.06
(3.31%)
After Hours
Reported EarningsNov 5
Mkt Cap$216.49M
Vol3.05M

About PYXS

Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The firm focuses on the development of product candidates to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. The company was founded by David Steinberg, Shaan C. Gandhi, and John L. Flavin on June 11, 2018 and is headquartered in Boston, MA.
76

Extremely Bullish Sentiment

How do you feel about PYXS?

BiotechSwings
$PYXS is still running imo up 12.8% this morning to 1.89 after Thursday closed up 19.1% at 1.68 on 1.8 million shares MICVO Phase 1 in head and neck cancer after prior therapy, 33 evaluable patients 39% confirmed responses, 94% disease control, median PFS 6.7 months vs 4.2 months on prior therapy, one complete response in there too William Blair upgraded it to Outperform this morning, HC Wainwright kept Buy at 8, and Phase 3 is planned for mid 2027 old options in this setting answer under 15% of the time. 39% is not a small beat ngl
6
W1llsterl1
$PYXS update call this morning was pretty bullish, learning to manage side effects well and good response in most patients thus far. Kept hinting at good news to report on the next combo trial in a couple weeks
4
focafoca99
$PYXS reporting updated Phase 1 MICVO data with 39% ORR and 81% 12-month OS, and will webcast results Nov 19.
3
Mkratz2021
$PYXS at this point i am holding until mid 2027. May grab another 1000 if it slips umder 1.40.
2
Rayvio_News_Filter
$PYXS 🏥 Pyxis Oncology, Inc. reported updated Phase 1 monotherapy data for MICVO in 2L+ R/M HNSCC showing a 39% confirmed ORR, 9.2-month median duration of response, and 6.7-month median PFS, supporting a planned Phase 3 trial. Timely market event
2

Advertisement|Remove ads.